Hosted on MSN1h
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after ...
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Supernus Pharmaceuticals (SUPN) to Release Earnings on Tuesday
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes ...
Hosted on MSN4d
Supernus’s stock sinks after depression drug fails trial
Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
BioSpace4d
Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
pharmaphorum5d
Supernus reports less than super data for depression drug
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...
FierceBiotech5d
Options shrink for Supernus depression drug candidate after key trial failure
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
Cantor downgrades Supernus on ‘disappointing’ depression study
Cantor Fitzgerald last night downgraded Supernus (SUPN) to Neutral from Overweight with a price target of $36, down from $57. The firm cites ...
Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Neutral Rating by Cantor Fitzgerald
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued ...
Supernus' Shares Fall 22% After Depression Study Misses Endpoint
Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression.
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...